Bob Lechleider
Directeur Technique/Scientifique/R&D chez IMMUNOME, INC.
Postes actifs de Bob Lechleider
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| IMMUNOME, INC. | Directeur Technique/Scientifique/R&D | 19/10/2023 | - |
Historique de carrière de Bob Lechleider
Anciens postes connus de Bob Lechleider
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
OncoResponse, Inc.
 OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | Directeur Technique/Scientifique/R&D | 01/04/2020 | 01/10/2023 |
| SEAGEN INC. | Directeur Technique/Scientifique/R&D | - | 01/01/2023 |
Formation de Bob Lechleider
| Princeton University | Undergraduate Degree |
| University of Illinois College of Medicine | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 6 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 3 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| IMMUNOME, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | Health Technology |
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
- Bourse
- Insiders
- Bob Lechleider
- Expérience
